Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference.

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a persons genetic make­up or a tumors genetic profile. As a result, patients with lung cancer now typically re­ceive molecular testing that guides their physicians in determining which therapies are more likely to boost the chances of survival while limiting the potential for adverse effects. Results from studies evaluating ALK-inhibitors continue to show efficacy and initial studies exploring immunomodulatory approaches using anti-PD-1 and anti-PD-L1 antibodies have demonstrated promising results in lung cancer. The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.

CancerConnect News coverage of advances in the management of lung cancer included the following key developments:

Lung Cancer Screening

Important Step Toward Widespread Use Of Low-Dose Computed Tomography Lung Cancer Screening In The United States

5 Things Women Should Know about Lung Cancer

2015 FDA News

Alecensa Approved for the Treatment of Recurrent ALK-Positive Lung Cancer

Novel Precision Medicine Tagrisso Approved for Treatment of Lung Cancer

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer

Iressa® Approved as Initial Therapy for Lung Cancer

FDA Grants Alectinib Priority Review for ALK-Positive Lung Cancer

FDA Approves Iressa for Treatment of Patients with Metastatic Non Small Cell Lung Cancer

Novel PD-1 Inhibitor Opdivo Approved for Treatment of Lung Cancer

FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer

NSCLC Research

Encouraging News For Patients With Treatment-Resistant Lung Cancer

Patients With Early-Stage Melanoma And Lung Cancer Among Those Standing To Benefit From Immunotherapy

Alectinib Produces High Anti-Cancer Activity in Recurrent Lung Cancer

Early Results of Opdivo® Combined with Yervoy® Presented at 16th World Conference on Lung Cancer

Updated Trial Results Demonstrating Benefit of Opdivo® Released at the 16th World Conference on Lung Cancer

New Targeted Drug Offers Promising Treatment Option in Resistant EGFR-Positive Lung Cancers

Xilonix Promising as Treatment for NonSmall Cell Lung Cancer

NFCR-Support Research Finds New Way to Combat Resistant Lung Cancer

Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC

Radiation Therapy

Stereotactic Body Radiation Therapy Improves Survival in Stage IV Non Small Cell Lung Cancer and Represents New Treatment Option

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer

Non-Small Cell Lung Cancer: The ALCHEMIST Lung Cancer Trials

Innovative Clinical Trials for Lung Cancer Currently Underway

More NSCLC News

New Lab Test Enables Precision Treatment for Lung Cancer

Aetna Provides Coverage for Biodesix VeriStrat Test

EGFR Testing in Advanced Lung Cancer Appears Underutilized


Sutent® Maintenance Therapy Found Active in Small-Cell Lung Cancer



Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey?

  • Sign up for monthly newsletters on lung cancer here.
  • Get the facts about lung cancer here.
  • Join ongoing discussions with other individuals affected by lung cancer in the CancerConnect private online support group here.
  • Follow CancerConnect on Facebook and Twitter.

Copyright © 2018 CancerConnect. All Rights Reserved.